On March 18 and March 19, 2020, respectively, the European Commission and the US Federal Trade Commission cleared the proposed acquisition of select Danaher businesses by Sartorius.
Both approvals are an important milestone for the transaction originally announced in October 2019, the completion of which is still subject to clearance by the Chinese antitrust enforcement authority of Sartorius as the buyer of the assets. The transaction is now expected to close in the second quarter of 2020.
The businesses to be acquired are part of Danaher’s Life Sciences platform and include various laboratory and bioprocessing technologies that are complementary to the portfolios of both Sartorius divisions.
These businesses will ultimately be a part of the Sartorius Bioprocess Solutions Division. Due to this expanded scope, the purchase price was increased by around 75 million US dollars to approximately 825 million US dollars.
Full Content: Yahoo
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
